Family Medicine Residency Program, King Abdulaziz Medical City, National Guard Health Affairs, King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Department of Medical Education, King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia.
NPJ Prim Care Respir Med. 2019 Feb 18;29(1):4. doi: 10.1038/s41533-019-0116-z.
Asthma is a chronic lung disease characterized by airway inflammation and hyper-responsiveness of airway smooth muscles. There is growing evidence that magnesium may have a role in managing asthma through its dual effect as an anti-inflammatory and bronchodilating agent. To assess the efficacy of oral magnesium supplements in chronic asthmatic patients. In addition to searching through Clinicaltrials.gov/ and references for oral magnesium supplement studies, we performed a database search in Medline, CINAHL, CENTRAL, and Embase. We contacted the authors of the included trials to ask for additional information. We included randomized controlled trials that compared oral magnesium supplements versus placebo, in addition to standard asthma treatment in mild-moderate asthmatic adults and children (older than 6 years). Two reviewers independently performed the study selection, data abstraction, and the assessment of the risk of bias. Eight trials at moderate risk of bias enrolling a total of 917 patients were included. Oral magnesium improved FEV1 at week 8 (5.69 (L/min); 95% CI: 1.92, 9.46; I: 45%). There was no significant improvement in FEV1 at other follow up periods. There was no significant change in FVC, Methacholine challenge test, the frequency of bronchodilator use, or symptoms score. There were no data on mortality or quality of life. Oral magnesium supplements may lead to improvement in FEV1 that was only demonstrated at eight weeks; but no effect on any other outcome. Until future evidence emerges, oral magnesium cannot be recommended as adjuvants to standard treatment for mild to moderate asthmatic individuals.
哮喘是一种慢性肺部疾病，其特征是气道炎症和气道平滑肌的高反应性。越来越多的证据表明，镁可能通过其作为抗炎和支气管扩张剂的双重作用在管理哮喘方面发挥作用。评估口服镁补充剂在慢性哮喘患者中的疗效。除了在 Clinicaltrials.gov/ 和参考文献中搜索口服镁补充剂研究外，我们还在 Medline、CINAHL、CENTRAL 和 Embase 中进行了数据库搜索。我们联系了纳入试验的作者，以获取更多信息。我们纳入了比较口服镁补充剂与安慰剂以及标准哮喘治疗在轻度至中度哮喘成年和儿童（6 岁以上）中的随机对照试验。两名审查员独立进行了研究选择、数据提取和偏倚风险评估。纳入了 8 项偏倚风险为中度的试验，共纳入 917 名患者。口服镁在第 8 周改善了 FEV1（5.69（L/min）；95%CI：1.92，9.46；I：45%）。在其他随访期间，FEV1 没有显著改善。FVC、乙酰甲胆碱挑战试验、支气管扩张剂使用频率或症状评分均无显著变化。没有关于死亡率或生活质量的数据。口服镁补充剂可能会导致 FEV1 的改善，但仅在 8 周时显示；但对任何其他结果均无影响。在未来的证据出现之前，不能推荐口服镁作为轻度至中度哮喘患者标准治疗的辅助治疗。
